Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein



I	</th <th>(</th> <th>ר</th> <th>IJ</th> <th>5</th>	(ר	IJ	5
ı	\ /		•	J	J

Description				
Source	Recombinant Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.			
	It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide.			
Accession	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAGGVGK			
Molecular Weight	The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result.			
Endotoxin	Less than 1EU per μg by the LAL method.			
Purity	> 95% as determined by Bis-Tris PAGE			
Fullty	> 95% as determined by HPLC			

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.


Assay Data

Bis-Tris PAGE



Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer is greater than 95% as determined by SEC-HPLC.